ArticleFood science & nutrition2026
Unraveling the Bioactive Compounds and Multi-Target Mechanisms of the Fructus Aurantii Immaturus-Bambusae Caulis in Taeniam Herb Pair Against Chronic Gastritis: Integrating Identification of Absorbed Constituents, Targeted Network Pharmacology, and Computational Validation.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic gastritis is a prevalent global health concern, and there is growing interest in functional foods and nutraceuticals derived from traditional herbs as complementary approaches for gastrointestinal health management. The Fructus Aurantii Immaturus-Bambusae Caulis in Taeniam (FAI-BCT) herb pair exhibits health-promoting effects against chronic gastritis, but the underlying molecular mechanisms, particularly of its bioactive constituents, remain unclear. We established an ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS/MS) method to identify the blood-absorbed constituents and metabolites of FAI-BCT in rat plasma. Combined with GEO database mining and targeted network pharmacology, molecular docking and molecular dynamics simulations were further performed to explore its anti-gastritis mechanisms. 27 prototype components and 13 metabolites were identified or preliminarily characterized in plasma. Targeted network pharmacology identified 3',4',5,7-tetramethoxyflavone, 5'-methoxynobiletin (M5), naringenin, hesperetin, p-coumaric acid, ferulic acid, and nobiletin as key bioactive compounds. Core therapeutic targets included epidermal growth factor receptor (EGFR), signal transducer and activator of transcription 3 (STAT3), B-cell lymphoma 2 (BCL2), matrix metalloproteinase-9 (MMP9), protein kinase B-α (AKT1), and prostaglandin-endoperoxide synthase 2 (PTGS2). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses highlighted the PI3K-Akt signaling pathway as a key mechanism regulated by these compounds. Molecular docking verified strong binding affinities, and molecular dynamics simulations validated stable complex formations. This study elucidates the multi-target mechanisms of FAI-BCT in preventing and managing chronic gastritis, emphasizing the role of its highly bioavailable bioactive constituents. The findings provide robust evidence supporting FAI-BCT's potential application in functional foods or nutraceuticals for chronic gastritis and underscore the importance of bioavailability-focused research on traditional Chinese medicine (TCM) constituents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.